Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Thermo Fisher Scientific Inc. has received a consensus recommendation of "Moderate Buy" from twenty-one research firms, with an average price target of $585.37.
• Insiders have recently sold a significant number of shares, including CEO Marc N. Casper, who sold 10,000 shares at an average price of $500.96.
• The company announced a quarterly dividend of $0.43, representing an annual yield of 0.3%, with the ex-dividend date set for September 15th.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-one research firms that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $585.3684.

Several equities research analysts have recently weighed in on TMO shares. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. HSBC reissued a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Evercore ISI decreased their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company's stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC grew its holdings in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the last quarter. Apella Capital LLC boosted its position in Thermo Fisher Scientific by 10.5% during the first quarter. Apella Capital LLC now owns 600 shares of the medical research company's stock worth $272,000 after acquiring an additional 57 shares during the last quarter. Retirement Planning Group LLC grew its stake in Thermo Fisher Scientific by 41.6% in the 1st quarter. Retirement Planning Group LLC now owns 640 shares of the medical research company's stock worth $318,000 after acquiring an additional 188 shares during the period. Finally, Breakwater Capital Group raised its holdings in Thermo Fisher Scientific by 47.0% in the 1st quarter. Breakwater Capital Group now owns 960 shares of the medical research company's stock valued at $478,000 after acquiring an additional 307 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 3.6%

TMO opened at $543.88 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $610.97. The business's 50 day moving average is $482.58 and its two-hundred day moving average is $447.76. The firm has a market cap of $205.37 billion, a price-to-earnings ratio of 31.46, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 EPS. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.